No Data
Wuhan Keqian Biology Co., Ltd (688526.SH): Plans to sign a cooperative research and development agreement with Huazhong Agricultural University.
On December 9th, Gelonghui reported that wuhan keqian biology co.,ltd (688526.SH) announced that in order to enhance the company's market competitiveness and accelerate the development in the biological product industry, thereby better enhancing the company's brand influence and core competitiveness, according to the "Articles of Association," "Cooperative Research and Development Management System," and other regulations, after competitive negotiations with Huazhong Agricultural University, the company has obtained a trivalent inactivated vaccine for chicken infectious rhinitis (Type A + Type B + Type C, recombinant protein), chicken Mycoplasma synoviae, chicken Mycoplasma gallisepticum (HB03 strain + HB15 strain), recombinant Newcastle disease virus, infectious bronchitis virus, and bird flu virus (H9 subtype), and infectious law.
wuhan keqian biology co.,ltd (688526.SH): has repurchased 0.4296% of the shares accumulated.
On November 4, Gelonhui announced that as of October 31, 2024, Wuxi Keqian Biology Co., Ltd. (688526.SH) has repurchased a total of 2,002,347 shares of the company through the Shanghai Stock Exchange trading system in a centralized competitive bidding trading manner, accounting for 0.4296% of the company's total share capital of 466,128,056 shares. The highest repurchase price was 18.90 yuan/share, the lowest price was 13.29 yuan/share, and the total amount paid was RMB 32,945,273.72 (excluding stamp duty, trading commissions, and other trading expenses).
Keqian Biology: Report of Wuhan Keqian Biology Co., Ltd. Third Quarter 2024
Wuhan Keqian Biology Co., Ltd. Report for the Third Quarter of 2024
Major shareholder wuhan keqian biology co.,ltd (688526.SH), supervisor Ye Changfa completed the shareholding of 1.8 million shares.
Wuhan Keqian Biology Co.,Ltd (688526.SH) announced that shareholder, supervisor Ye Changfa, holding more than 5% of the shares, conducted block trading...
Wuhan Keqian Biology Co., Ltd. (688526.SH): The actual controller renews the consistent action agreement with the controlling parties.
On September 20th, Keqian Biology (688526.SH) announced that it has received a notice from Mr. He Qigai, Mr. Wu Bin, Ms. Fang Liurong, and Mr. Wu Meizhou, the actual controllers of the company, regarding the renewal of the "Consistent Action Agreement". Since the "Consistent Action Agreement" signed by all parties on September 22, 2023 is about to expire, in order to improve corporate governance, ensure the continuity and stability of the company's operation, and achieve substantive and effective control over the company, all parties have renewed the "Consistent Action Agreement".
